

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (original). A pharmaceutical and/or veterinary formulation comprising about 2-15 % (w/w) of at least one peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-3.5 % (w/w) lecithin and the balance stearin.

2 (original). A formulation according to claim 1, wherein the formulation comprises about 5-10 % (w/w) peptide agonist or analogue other than deslorelin (on an active basis), about 0.5-1.5 % (w/w) lecithin and about 89-94 % (w/w) stearin.

3 (currently amended). A formulation according to claim 1 ~~or~~ 2, wherein the formulation comprises about 5 % (w/w) peptide agonist or analogue other than deslorelin (on an active basis), 1 % (w/w) lecithin and 94 % (w/w) stearin.

4 (currently amended). A formulation according to claim 1 ~~or~~ 2, wherein the formulation comprises about 5 % (w/w) peptide agonist or analogue other than deslorelin (on an active basis), 2 % (w/w) lecithin and 93 % (w/w) stearin.

5 (currently amended). A formulation according to ~~any one of the preceding claims~~ claim 1, wherein the formulation is for administration to humans.

6 (currently amended). A formulation according to ~~any one of the preceding claims~~claim 1, wherein the at least one peptide agonist or analogue is a GnRH agonist or analogue other than deslorelin.

7 (original). A formulation according to claim 6, wherein the GnRH agonist or analogue is selected from the group consisting of goserelin, leuprorelin, triptorelin, meterelin, buserelin, histrelin, nafarelin, and combinations thereof.

8 (currently amended). A method of treating a disease or condition in an animal, the method comprising administering to the animal the formulation of ~~any one of the preceding claims~~claim 1.

9 (currently amended). A method of treating a disease or condition in an animal for which suppression of sex hormone levels is beneficial, the method comprising administering to the animal the formulation of claim 6 ~~or 7~~.

10 (original). A method according to claim 9, wherein the disease or condition is selected from prostate cancer, ovarian and breast cancer, endometriosis, myoma, premenstrual tension, uterine fibroids, hirsutism, cyclic auditory dysfunction, porphyria and precocious puberty.

11 (currently amended). A method of preventing reproductive function in an animal, the method comprising administering to the animal the formulation of claim 6 ~~or~~

7.

12 (original). A method of treating benign prostatic hyperplasia in an animal, the method comprising administering to the animal a formulation comprising about 2-10 % (w/w) GnRH agonist or analogue (on an active basis), about 0.5-2.5 % (w/w) lecithin and the balance stearin.

13 (original). A method according to claim 12, wherein the formulation comprises about 5-10 % (w/w) GnRH agonist or analogue (on an active basis), about 0.5-1.5 % (w/w) lecithin and about 89-94% (w/w) stearin.

14 (currently amended). A method according to claim 12 ~~or 13~~, wherein the GnRH agonist or analogue is selected from the group consisting of deslorelin, goserelin, leuprorelin, triptorelin, meterelin, buserelin, histrelin, nafarelin and combinations thereof.

15 (original). A method according to claim 14, wherein the at least one GnRH agonist is deslorelin.

16 (currently amended). A method according to ~~any one of claims 12 to 15~~claim 12, wherein the formulation utilised is for administration to dogs.